<DOC>
	<DOC>NCT02618759</DOC>
	<brief_summary>The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS compared to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.</brief_summary>
	<brief_title>Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis</brief_title>
	<detailed_description>To evaluate the therapeutic efficacy and safety of dsxs topical spray, 0.15% (Taro Pharmaceuticals, U.S.A., Inc.) compared to a Placebo (vehicle) spray (Taro Pharmaceuticals, U.S.A., Inc.) in patients with mild to moderate plaque psoriasis.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>male and nonpregnant females, 12 years of age or older, with a confirmed diagnosis of mild to moderate plaque psoriasis patient is&lt; 12 years old.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>